吸入薬市場の2030年までの予測：薬剤クラス別、流通チャネル別、用途別、地域別の世界分析

Stratistics MRCによると、世界の吸入薬市場は2023年に343億米ドルを占め、予測期間中に8.8％のCAGRで成長し、2030年までに619億米ドルに達すると予想されています。

吸入薬市場には、呼吸器疾患や全身疾患をターゲットに、吸入経路を通じて送達される医薬品が含まれます。吸入薬は呼吸器系に直接投与されるため、血流への迅速な吸収と局所的な治療効果を可能にします。吸入可能な薬剤市場は、現代医学において重要な役割を果たし、様々な呼吸器疾患や全身疾患の治療に革新的なソリューションを提供しています。吸入可能な薬剤は、吸入器やネブライザーを通じて投与され、呼吸器系に直接、迅速かつ的を絞ったデリバリーを提供し、効率的な吸収と作用の発現を保証します。

米国疾病予防管理センター（CDC）によると、2021年には米国で2,500万人以上が喘息に罹患しており、成人の約8.0％、小児の約6.5％を占めています。世界保健機関（WHO）が2022年10月に発表した論文によると、世界全体では、60歳以上の高齢者の割合は2015年の12％から2050年には22％へと2倍に増加するとみられています。

呼吸器疾患の増加

喘息、慢性閉塞性肺疾患（COPD）、嚢胞性線維症などの呼吸器系疾患の有病率の増加は、吸入薬市場の著しい成長に拍車をかけています。これらの疾患が世界的に流行するにつれ、効果的な治療オプションに対する需要が高まっています。吸入薬は従来の経口薬に比べて、肺への直接の標的デリバリー、迅速な作用発現、全身的な副作用の軽減など、いくつかの利点があります。さらに、吸入技術の進歩により革新的な送達デバイスが開発され、患者の利便性と治療レジメンのアドヒアランスが向上しています。

吸入薬を誤用するリスク

吸入薬はレクリエーション目的で意図的に、あるいは不適切な投与技術により意図せずに誤用される可能性があります。特に精神作用のある薬剤では、乱用の可能性があります。このような誤用は、治療効果を損なうだけでなく、患者の安全や規制遵守に関する懸念も生じさせる。そのため、ヘルスケアプロバイダーや規制当局は、誤用のリスクを軽減するために厳格な監視と教育を重視しており、市場の拡大を制限する可能性があります。

生物製剤の吸入投与の可能性

吸入可能な生物製剤デリバリーの出現は、より効率的で患者に優しい投与方法を提供することで、吸入可能ドラッグ市場を大幅に強化しています。生物に由来する大きな分子である生物製剤は、喘息、慢性閉塞性肺疾患（COPD）、嚢胞性線維症などの様々な慢性疾患の治療状況に革命をもたらしました。生物学的製剤を吸入する可能性は、非侵襲的で針を使わない選択肢を提示し、多くの呼吸器疾患が発生する肺に直接投与することを可能にします。これは患者の快適性とアドヒアランスを向上させるだけでなく、標的への送達と全身的副作用の軽減によって治療成績を改善する可能性があります。

高い開発コスト

高い開発コストは吸入薬市場において大きな障壁となり、イノベーションと新製品のイントロダクションを阻害します。吸入薬の複雑な開発プロセスには、広範な調査、臨床試験、規制当局の承認が含まれ、これらすべてに多額の費用がかかります。製薬会社はしばしば、こうした高いコストと潜在的な市場需要や収益性とのバランスをとるという課題に直面します。しかし、吸入ドラッグデリバリーシステムは複雑であるため、高度な技術と専門知識が必要とされ、開発費の高騰にさらに拍車をかけています。

COVID-19の影響：

ウイルスの呼吸器系への感染に伴い、呼吸器系ドラッグデリバリーシステムへの注目が高まり、吸入可能な薬剤への需要が高まった。呼吸困難などのCOVID-19の症状に対する効果的な治療法の必要性から、吸入可能な薬剤の研究開発が急増しました。ロックダウンや社会的距離を置く措置がサプライチェーンや流通網を混乱させ、生産と流通の一時的な後退を引き起こしました。ヘルスケアシステムはCOVID-19管理を優先し、吸入薬で通常治療される呼吸器疾患を含む他の病状から注意とリソースをそらしました。

予測期間中、ロイコトリエン修飾薬セグメントが最大となる見込み

ロイコトリエン修飾薬セグメントは予測期間中に最大となる見込みです。ロイコトリエンによって媒介される炎症経路を標的とすることで、これらの薬剤は呼吸器疾患、特に世界中で数百万人が罹患している喘息を管理するための新しいアプローチを提供します。従来の気管支拡張薬とは異なり、ロイコトリエン修飾薬はロイコトリエンの産生または作用を阻害することによって作用し、それによって気道の炎症と収縮を抑制します。このメカニズムは症状の緩和をもたらすだけでなく、喘息の増悪を予防し、肺機能全体を改善するのにも役立ちます。

予測期間中、小売薬局セグメントが最も高いCAGRが見込まれる

小売薬局セグメントは、予測期間中にCAGRが最も高くなると予想されます。なぜなら、これらの薬局は入手しやすい流通拠点として機能し、吸入可能な薬剤を消費者が容易に入手できるようにするからです。喘息やCOPDのような呼吸器疾患の有病率の増加に伴い、近くの薬局で吸入薬を入手できる利便性は、患者の治療レジメンへのアドヒアランスを著しく向上させる。さらに、小売薬局はしばしば患者教育やカウンセリング・サービスを提供し、適切な吸入技術や服薬管理を支援しています。さらに、小売薬局は技術革新の拠点として機能し、新しい吸入式製剤やドラッグデリバリー機器を在庫しているため、進化する患者のニーズや嗜好に対応することで市場の成長を促進しています。

最大のシェアを占める地域：

予測期間中、アジア太平洋地域が市場で最大のシェアを占めると予想されます。同地域の国々はヘルスケア・インフラやサービスへの投資を増やしており、吸入可能な薬剤を含む革新的なドラッグ・デリバリー・システムへの注目が高まっています。中間所得層の増加とライフスタイルの変化が呼吸器疾患の増加に寄与し、同地域における吸入薬の需要をさらに押し上げています。アジア太平洋地域ではヘルスケア支出が急増し続けており、製薬会社は吸入可能な薬剤製剤の研究開発にますます投資するようになっているため、同地域の吸入薬市場の成長を促進しています。

CAGRが最も高い地域：

アジア太平洋地域は、予測期間中に有益な成長を示すと推定されます。アジア太平洋地域の政府規制は、技術革新、安全性、アクセシビリティに有利な環境を育成することで、吸入薬市場を強化する上で重要な役割を果たしています。医薬品登録の承認プロセスや製造基準などの規制の枠組みは、吸入薬が市場に出回る前に厳しい品質と有効性の基準を満たすことを保証しています。その結果、政府の規制は公衆衛生を守るだけでなく、アジア太平洋地域における吸入薬市場の成長を促進しました。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 用途分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の吸入薬市場：薬剤クラス別

• 長時間作用型ベータ拮抗薬（LABA）
• 吸入コルチコステロイド
• 長時間作用型ムスカリン拮抗薬（LAMA）
• ロイコトリエン修飾薬
• その他の薬剤クラス

第6章 世界の吸入薬市場：流通チャネル別

• オンライン薬局
• 小売薬局
• 病院薬局
• その他の流通チャネル

第7章 世界の吸入薬市場：用途別

• 呼吸器系以外の疾患
• 呼吸器疾患
• その他の用途

第8章 世界の吸入薬市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイリング

• AstraZeneca
• Boehringer Ingelheim International GmbH
• Cipla Inc
• GlaxoSmithKline plc
• Merck & Co., Inc
• Mundipharma International
• Novartis International AG
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd
• Vectura Group Ltd
• Viatris Inc

List of Tables

• Table 1 Global Inhalable Drugs Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 3 Global Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
• Table 4 Global Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
• Table 5 Global Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
• Table 6 Global Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
• Table 7 Global Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 8 Global Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 9 Global Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 10 Global Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 11 Global Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 12 Global Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 13 Global Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
• Table 14 Global Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
• Table 15 Global Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 16 Global Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 17 North America Inhalable Drugs Market Outlook, By Country (2021-2030) ($MN)
• Table 18 North America Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 19 North America Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
• Table 20 North America Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
• Table 21 North America Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
• Table 22 North America Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
• Table 23 North America Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 24 North America Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 25 North America Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 26 North America Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 27 North America Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 28 North America Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 29 North America Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
• Table 30 North America Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
• Table 31 North America Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 32 North America Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 33 Europe Inhalable Drugs Market Outlook, By Country (2021-2030) ($MN)
• Table 34 Europe Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 35 Europe Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
• Table 36 Europe Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
• Table 37 Europe Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
• Table 38 Europe Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
• Table 39 Europe Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 40 Europe Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 41 Europe Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 42 Europe Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 43 Europe Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 44 Europe Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 45 Europe Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
• Table 46 Europe Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
• Table 47 Europe Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 48 Europe Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 49 Asia Pacific Inhalable Drugs Market Outlook, By Country (2021-2030) ($MN)
• Table 50 Asia Pacific Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 51 Asia Pacific Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
• Table 52 Asia Pacific Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
• Table 53 Asia Pacific Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
• Table 54 Asia Pacific Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
• Table 55 Asia Pacific Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 56 Asia Pacific Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 57 Asia Pacific Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 58 Asia Pacific Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 59 Asia Pacific Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 60 Asia Pacific Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 61 Asia Pacific Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
• Table 62 Asia Pacific Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
• Table 63 Asia Pacific Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 64 Asia Pacific Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 65 South America Inhalable Drugs Market Outlook, By Country (2021-2030) ($MN)
• Table 66 South America Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 67 South America Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
• Table 68 South America Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
• Table 69 South America Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
• Table 70 South America Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
• Table 71 South America Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 72 South America Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 73 South America Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 74 South America Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 75 South America Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 76 South America Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 77 South America Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
• Table 78 South America Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
• Table 79 South America Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 80 South America Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 81 Middle East & Africa Inhalable Drugs Market Outlook, By Country (2021-2030) ($MN)
• Table 82 Middle East & Africa Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 83 Middle East & Africa Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
• Table 84 Middle East & Africa Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
• Table 85 Middle East & Africa Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
• Table 86 Middle East & Africa Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
• Table 87 Middle East & Africa Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 88 Middle East & Africa Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 89 Middle East & Africa Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 90 Middle East & Africa Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 91 Middle East & Africa Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 92 Middle East & Africa Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 93 Middle East & Africa Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
• Table 94 Middle East & Africa Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
• Table 95 Middle East & Africa Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 96 Middle East & Africa Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)

According to Stratistics MRC, the Global Inhalable Drugs Market is accounted for $34.3 billion in 2023 and is expected to reach $61.9 billion by 2030 growing at a CAGR of 8.8% during the forecast period. The inhalable drugs market encompasses pharmaceutical products delivered through inhalation routes, targeting respiratory conditions or systemic diseases. Inhalable drugs are administered directly to the respiratory system, allowing for rapid absorption into the bloodstream and localized therapeutic effects. The inhalable drugs market serves as a vital avenue in modern medicine, offering innovative solutions for the treatment of various respiratory diseases and systemic conditions. Inhalable drugs, administered through inhalers or nebulizers, provide rapid and targeted delivery directly to the respiratory system, ensuring efficient absorption and onset of action.

According to the Centers for Disease Control and Prevention (CDC), more than 25 million people had asthma in the U.S. in 2021, accounting for approximately 8.0% of adults and 6.5% of children. According to an article released by the World Health Organization in October 2022, globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050.

Market Dynamics:

Driver:

Rising prevalence of respiratory diseases

The increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis has spurred significant growth in the inhalable drugs market. As these conditions become more prevalent globally, the demand for effective treatment options has escalated. Inhalable drugs offer several advantages over traditional oral medications, including targeted delivery directly to the lungs, rapid onset of action, and reduced systemic side effects. Additionally, advancements in inhalation technology have led to the development of innovative delivery devices, improving patient convenience and adherence to treatment regimens.

Restraint:

Risk of misusing inhalable medications

Inhalers can be misused intentionally for recreational purposes or unintentionally due to improper administration techniques. There's a potential for abuse, particularly with medications that have psychoactive effects. Such misuse not only compromises the effectiveness of the treatment but also raises concerns regarding patient safety and regulatory compliance. Consequently, healthcare providers and regulatory agencies emphasize stringent monitoring and education to mitigate the risk of misuse, which can potentially limit the market's expansion.

Opportunity:

Possibility of inhaling biologics delivery

The emergence of inhalable biologics delivery has significantly bolstered the Inhalable Drugs Market by offering a more efficient and patient-friendly administration method. Biologics, which are large molecules derived from living organisms, have revolutionized the treatment landscape for various chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. The possibility of inhaling biologics presents a non-invasive, needle-free alternative, allowing for direct delivery to the lungs where many respiratory diseases originate. This not only enhances patient comfort and adherence but also potentially improves therapeutic outcomes through targeted delivery and reduced systemic side effects.

Threat:

High development costs

High development costs act as a significant barrier in the inhalable drugs market, impeding innovation and the introduction of new products. The intricate process of developing inhalable drugs involves extensive research, clinical trials, and regulatory approvals, all of which incur substantial expenses. Pharmaceutical companies often face the challenge of balancing these high costs with potential market demand and profitability. However, the complexity of inhalable drug delivery systems necessitates sophisticated technologies and expertise, further contributing to elevated development expenses.

Covid-19 Impact:

With the respiratory nature of the virus, there was an increased focus on respiratory drug delivery systems, driving demand for inhalable drugs. The need for effective treatments for Covid-19 symptoms, such as respiratory distress, led to a surge in research and development of inhalable medications. Lockdowns and social distancing measures disrupted the supply chain and distribution networks, causing temporary setbacks in production and distribution. Healthcare systems prioritized Covid-19 management, diverting attention and resources away from other medical conditions, including respiratory diseases typically treated with inhalable drugs.

The leukotriene modifiers segment is expected to be the largest during the forecast period

Leukotriene Modifiers segment is expected to be the largest during the forecast period. By targeting the inflammatory pathway mediated by leukotrienes, these medications offer a novel approach to managing respiratory conditions, particularly asthma, which affects millions worldwide. Unlike traditional bronchodilators, leukotriene modifiers work by inhibiting the production or action of leukotrienes, thereby reducing airway inflammation and constriction. This mechanism not only provides symptom relief but also helps in preventing asthma exacerbations and improving overall lung function.

The retail pharmacies segment is expected to have the highest CAGR during the forecast period

Retail Pharmacies segment is expected to have the highest CAGR during the forecast period as these pharmacies serve as accessible points of distribution, making inhalable drugs readily available to consumers. With the increasing prevalence of respiratory ailments like asthma and COPD, the convenience of obtaining inhalable medications from nearby pharmacies significantly improves patient adherence to treatment regimens. Moreover, retail pharmacies often offer patient education and counseling services, aiding in proper inhaler technique and medication management. Furthermore, retail pharmacies serve as hubs for innovation, stocking new inhalable drug formulations and delivery devices, thus driving market growth by catering to evolving patient needs and preferences.

Region with largest share:

Asia Pacific region is expected to hold the largest share of the market over the projected period. As countries in the region invest more in healthcare infrastructure and services, there is an increased focus on innovative drug delivery systems, including inhalable drugs. The growing middle-class population and changing lifestyles contribute to the rise in respiratory disorders, further driving the demand for inhalable drugs in the region. With healthcare spending continuing to surge in Asia Pacific, pharmaceutical companies are increasingly investing in research and development of inhalable drug formulations, thus propelling the growth of the inhalable drugs market in the region.

Region with highest CAGR:

Asia Pacific region is estimated to witness profitable growth during the extrapolated period. Government regulations in the Asia Pacific region have played a substantial role in enhancing the Inhalable Drugs Market by fostering a favorable environment for innovation, safety, and accessibility. Regulatory frameworks, such as the approval processes for drug registration and manufacturing standards, ensure that inhalable drugs meet stringent quality and efficacy standards before entering the market. As a result, government regulations have not only safeguarded public health but also catalyzed the growth of the inhalable drugs market in the Asia Pacific region.

Key players in the market

Some of the key players in Inhalable Drugs market include AstraZeneca, Boehringer Ingelheim International GmbH, Cipla Inc, GlaxoSmithKline plc, Merck & Co., Inc, Mundipharma International, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd and Viatris Inc.

Key Developments:

In November 2023, Sanofi, a pharmaceutical company, announced that Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating U.S. Food and Drug Administration submission and confirming potential to become first approved biologic for this serious disease

In July 2023, Viatris Inc., a global healthcare company, and Kindeva Drug Delivery L.P., a pharmaceutical contract development and manufacturing organization, launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first generic version of AstraZeneca's Symbicort with an abbreviated new drug application (ANDA) approved by the U.S. Food and Drug Administration (FDA).

In January 2023, AstraZeneca received approval from the U.S. Food and Drug Administration for Airsupra (albuterol and budesonide) inhalation aerosol. Airsupra aims to reduce the risk of asthma exacerbations in individuals aged 18 years and older.

In November 2022, PT027 had been recommended by the U.S.FDA Advisory Committee as new rescue treatment for asthma. T027 is a potential first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication in the U.S. containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS). It is being developed by AstraZeneca, a pharmaceutical company and Avillion, a global drug development company.

In March 2022, Viatris Inc. and Kindeva Drug Delivery L.P. received FDA approval for Breyna, a drug-device combination therapy recommended for patients with asthma or chronic obstructive pulmonary disease (COPD).

Drug Classes Covered:

• Long-acting Beta Antagonists (LABAs)
• Inhaled Corticosteroids
• Long-acting Muscarinic Antagonists (LAMAs)
• Leukotriene Modifiers
• Other Drug Classes

Distribution Channels Covered:

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies
• Other Distribution Channels

Applications Covered:

• Non-respiratory Diseases
• Respiratory Diseases
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Inhalable Drugs Market, By Drug Class

• 5.1 Introduction
• 5.2 Long-acting Beta Antagonists (LABAs)
• 5.3 Inhaled Corticosteroids
• 5.4 Long-acting Muscarinic Antagonists (LAMAs)
• 5.5 Leukotriene Modifiers
• 5.6 Other Drug Classes

6 Global Inhalable Drugs Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Online Pharmacies
• 6.3 Retail Pharmacies
• 6.4 Hospital Pharmacies
• 6.5 Other Distribution Channels

7 Global Inhalable Drugs Market, By Application

• 7.1 Introduction
• 7.2 Non-respiratory Diseases
• 7.3 Respiratory Diseases
• 7.4 Other Applications

8 Global Inhalable Drugs Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 AstraZeneca
• 10.2 Boehringer Ingelheim International GmbH
• 10.3 Cipla Inc
• 10.4 GlaxoSmithKline plc
• 10.5 Merck & Co., Inc
• 10.6 Mundipharma International
• 10.7 Novartis International AG
• 10.8 Pfizer Inc
• 10.9 Teva Pharmaceutical Industries Ltd
• 10.10 Vectura Group Ltd
• 10.11 Viatris Inc